Organic Active Ingredients TRIZ Cases

Novel pyrazino-triazinone reverse-turn mimetics inhibit acute myeloid leukemia cell proliferation through targeted Wnt signaling pathway blockade.

A process for preparing 7-alpha-[9-(4,4,5,5,5-pentafluorothiopentyl) nonyl]estra-1,3,5(10)-triene-3,17-beta-diol using stereospecific alkylation.

A miR-184 modulator regulates keratinocyte migration and differentiation to support tissue repair.

Agents modulate lymph node-innervating peptidergic nociceptor sensory neurons to regulate immune responses and homeostasis.

Oral liquid pharmaceutical compositions utilize extended-release aminosalicylate microparticles suspended in an aqueous carrier.

An antibody drug conjugate links an iridium N-heterocyclic carbene complex to trastuzumab via a cleavable peptide linker.

Topical exosome compositions recover discarded cell culture byproducts to treat dermatological conditions.

Pyrimidine compounds inhibit IKKε, TBK1, and SIK2 kinases while resolving inadequate pharmacokinetic properties.

A transdermal system uses a voltage-controlled matrix to maintain active substances in an ionic form for skin permeation.

Novel RORγ modulators target the receptor to treat autoimmune conditions where existing therapies lack effective modulation.

Targeted Clk1 inhibition drives white to beige adipocyte conversion, increasing UCP1 expression to reduce lipid storage and treat obesity.

Tramadol celecoxib co-crystals alter absorption rates and plasma concentration profiles, lowering abuse potential while sustaining analgesic efficacy.

A synergistic combination of caffeic acid and sinapic acid enhances antioxidant performance in food and cosmetic preparations.

Methylated cyclodextrins solubilize lipophilic compounds via hydrophobic cavity encapsulation.

6-cycloamino-3-pyridazinyl-imidazopyridazine derivatives provide novel therapeutic agents for disease management.

Intravenous sotalol hydrochloride infusion over 60 minutes achieves steady state Cmax levels for oral transition.

4-phenylbutyric acid mitigates endoplasmic reticulum stress, inhibiting the unfolded protein response pathway and reducing apoptosis in motor neurons.

Oral AZD1390 crosses the blood-brain barrier to inhibit ATM activation, resolving CNS delivery complexity while promoting axon regeneration.

Applying a polydatin topical preparation before treatment reduces skin rash and inflammatory responses caused by EGFR inhibitors.

Selective 3-amino piperidyl compounds inhibit NaV1.7 ion flux to relieve pain while minimizing adverse side effects from non-specific channel blockade.

Leucomethylthioninium salts replace chloroquine to treat COVID-19 without cardiotoxicity, improving safety for elderly populations.

Branched polyamine coester polymers resolve the contradiction between complexation stability and physiological fluid degradation through dynamic ester bonds.

Topical tranexamic acid blocks the plasminogen activation pathway, preventing radiation-induced dermatitis and mucositis during cancer radiotherapy.

Positive allosteric modulators extend therapeutic duration by amplifying endogenous GLP-1 activity, overcoming short half-life limitations.

Substituted pyrazolo[1,5-a]pyridine compounds inhibit RET kinase activity to treat cancers and manage chemotherapy-induced diarrhea.

Telomeric oligonucleotides activate endogenous DNA repair pathways like p53 and XPC to restore function in damaged cochlear outer hair cells.

Specific Lactobacillus strains convert anthocyanins into beneficial metabolites, addressing gut microbiota variability through colon-targeted release.

New TAF1 inhibitors overcome weak growth inhibition by selectively targeting the second bromodomain to advance clinical trial eligibility.

Combining A6 peptide with paclitaxel modulates CD44 receptors to enhance anti-cancer activity in ovarian cancer treatment.

BCAA-lowering compounds reduce amyloid and Tau pathology, improving glycemic control and restoring neurotransmitter levels to delay cognitive decline.

HDAC inhibitors modify cancer cell surfaces to boost macrophage recognition, overcoming the CD47 don't eat me signal and improving therapeutic efficacy.

Histidine residues in the YM3-10H peptide buffer negative RNA charges, preventing neutralization and enabling cellular uptake for therapeutic applications.

Irisin sensitizes malignant breast and prostate cancer cells to chemotherapy, reducing required drug doses while sparing non-malignant tissue.

Citric acid derivatives treat nonalcoholic steatohepatitis by combining citric acid and amino acids to lower AST and ALT levels without adverse effects.

Novel cyclopropylmethanamine compounds activate the 5-HT2C receptor with high selectivity over other subtypes.

Graphene nanostructures act as active ingredients to inhibit protein misfolding and fibril formation in neurodegenerative disease treatments.

Parameter changes reduce immunogenicity while maintaining protein production efficiency.

Modified benzenesulfonamide compounds enhance dopamine D3 receptor binding affinity through specific structural substitutions.

2-Alkoxy benzene formyl arylamine compounds inhibit sphingomyelin synthase to regulate lipid metabolism.

Steam bleaching and continuous screw expression recover rosmarinic acid from fresh plant material without drying or grinding.

Stable tianeptine oxalate crystalline forms enhance bioavailability and therapeutic efficacy through controlled polymorphic structures.

Anti-CD25 antibodies resolve high relapse rates in AML by depleting suppressive regulatory T cells and directly killing leukemic stem cells.

Compounds using stable spacers to enhance metabolic stability while maintaining high binding affinity for galectins in inflammatory and fibrotic diseases.

Incorporating ginger at 0.5 to 2 percent weight into complete pet food formulations reduces inflammatory markers and improves cartilage synthesis.

Magnesium aluminometasilicate prevents hydrate conversion of bilastine form 3, resolving stability and dissolution trade-offs.